Therapeutic-focused CRO Services

KCAS Bio has proven expertise across a range of disease and treatment areas. With more than 45 years of experience as a drug development CRO, we combine deep bioanalytical and biomarker experience with our reputation for consistency, transparency, and data integrity at every stage of your specific therapeutic focus area.

Talk to an expert

Therapeutic areas of focus

Allergy & immunology

We have extensive experience in developing, validating, and implementing immunological methods, including biomarker quantification and flow cytometry. Trust our team of experts to provide tailored solutions for your drug development needs.

Explore now
Oncology

KCAS Bio provides reliable data to advance immune-oncology treatments. From discovery to Phase III trials, we have experience in flow cytometry, ELISPOTs, and cell-based assays, alongside multiple biomarkers.

Explore now
Infectious diseases

In a post-COVID-19 world, trust a CRO with proven experience in infectious disease and vaccine development. KCAS stands ready, equipped with diverse platforms and techniques for your project success.

Explore now
Neurological

In a world witnessing a surge in brain disorders, our advanced neurosciences expertise is your ally from discovery to translation. Unlock the potential of neurological drug development with KCAS.

Explore now
Gastrointestinal

With a focus on experimental therapeutics, we address a spectrum of conditions including Crohn's disease and inflammatory bowel disease. Trust KCAS for a comprehensive approach to advance your project in the evolving landscape of gastrointestinal disorders.

Explore now
Ophthalmology

From compound identification to efficacy studies, we specialize in preclinical ophthalmic research. Our experienced team ensures milestone data accuracy for crucial early-stage decisions. Trust KCAS Bio for the complexities of your ophthalmology study.

Explore now
Rare diseases

Our validated 20-plex assay for 20 amino acids supports metabolism and rare disease research. Developing drugs for rare diseases demands specialized expertise, especially in cell and gene therapy. KCAS Bio stands out with a proven history and experience.

Explore now
Respiratory

We monitor immune system status during and after infection, offering flow cytometric immunophenotyping, cytokine profiling, and retrospective studies. With expertise in whole blood, PBMCs, and respiratory samples, we specialize in diseases like COPD, lung cancer, and pneumonia.

Explore now
Renal

Trust KCAS for expert renal/kidney testing. We develop assays, even for challenging compounds, ensuring quality data for drug development. With extensive experience, we understand the crucial role renal function plays in drug elimination.

Explore now
Cardiovascular

With 40+ years in pre-clinical research, we provide deep expertise in cardiovascular biomarkers and large molecule drugs. From target identification to drug development, trust us for comprehensive bioanalytical support at every stage of your cardiovascular drug project.

Explore now
Metabolic

Discover comprehensive support for metabolic drug development with KCAS. With a deep understanding of metabolic and endocrine diseases, we provide expert bioanalytical services from discovery to biologic development.

Explore now

Find exactly what you’re looking for

Search for specific services, platforms, instrumentation, or scientific insights.

Podcast (The Weekly Bioanalysis) Eps #102: “Evolving Science & Increasing Opportunities for Customer Interactions” Podcasts
Read article Podcast (The Weekly Bioanalysis) Eps #102: “Evolving Science & Increasing Opportunities for Customer Interactions”

The main discussion in Episode #102 explores what KCAS Bio scientific advisors are hearing from customers as face-to-face visits and industry interactions increase. The conversation highlights a major shift toward more complex therapeutics and targeted delivery strategies, including conjugates, protein shuttles, in vivo gene therapies, and technologies designed to…

From Whole Blood to Dose Decisions: Managing a 3-Year, Multi-Continent Bioanalytical Program for a Phase 1a/1b Trial  Blogs
Read article From Whole Blood to Dose Decisions: Managing a 3-Year, Multi-Continent Bioanalytical Program for a Phase 1a/1b Trial 

When a sponsor’s biologic program expanded from a domestic Phase 1 design into a multi-region trial spanning New Zealand, EMEA, and APAC, the bioanalytical challenge centered on keeping a fragile, time-sensitive sample chain intact across nine additional clinical sites, two outsourced processing labs, and a central analytical lab, all…

PBSS: From Preclinical to Clinical: Across Therapeutic Modalities Events November 3 - November 3

This symposium is for the drug development professional who wants to know more about how therapies of a variety of modalities move from preclinical through to clinical proof of concept. The preclinical data required and nice to have for optimal development as well as clinical design, planning and execution…

Agile, responsive, and easy to work with

We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.

Explore services